Patanjali Ayurved Limited Overview
Patanjali Ayurved Limited is the privately controlled flagship and brand-owning holding company of the Patanjali Group, the Haridwar-based Ayurveda-and-swadeshi consumer conglomerate co-founded by Acharya Balkrishna and Swami Ramdev. From incorporation in 2006, PAL scaled into one of India's fastest-growing FMCG companies by the mid-2010s. It did so on value pricing, Ayurvedic and herbal positioning, and Ramdev's mass yoga following. It reached roughly ₹10,000 crore of standalone revenue by FY2017 and peaked at ₹10,664 crore in FY2022. Since 2019 the company has re-engineered itself around its listed vehicle, Patanjali Foods, through three steps:
-
acquiring the insolvent Ruchi Soya;
-
transferring its food (2022) and home-and-personal-care (2024) businesses into PFL;
-
retaining brand ownership, Ayurvedic wellness, dairy, trading and strategic investments.
PAL is now pivoting into financial services via a ₹4,500 crore (100% valuation) acquisition of Magma General Insurance. It remains under heavy regulatory and judicial scrutiny over its advertising practices.
Company's own description
The Secretarial Audit Report annexed to PAL's FY2021-22 Annual Report describes PAL as follows:
-
an FMCG business spanning Ayurvedic products, foods and refreshment, home care, personal care and dairy products;
-
with manufacturing facilities across India;
-
selling primarily in India through independent distributors and exclusive stores.
The Board's Report frames the proposition as Ayurvedic, herbal, traditional and domestic products at reasonable prices, with profit described as not being the sole motive. In RoC-based reporting for FY2024, PTI described PAL's operations as follows:
-
the Ayurvedic product and FMCG business, primarily hair care, skin care, dental care, home care, personal care and dairy products;
-
plus bulk trading of food products.
Independent characterisation (as of October 2026)
PAL's business model has changed fundamentally since FY2022. It is best understood today as a hybrid of four things:
-
Brand-owning parent and promoter. PAL owns the "Patanjali" consumer franchise and is the single largest promoter of PFL. It held 29.61% of PFL at March 2026 (marketsmojo shareholding data). It earns from PFL through several channels:
-
related-party sales and purchases (PFL's AGM in September 2025 approved a revised material related-party transaction limit with PAL for FY2025-26);
-
royalties;
-
divestment proceeds — ₹690 crore for the food business in 2022, ₹1,100 crore for the HPC business in 2024, and OFS/secondary sales of PFL shares.
-
-
Residual operating FMCG/Ayurveda company. After two business transfers, PAL's revenue from operations fell from ₹10,664 crore (FY2022) to ₹6,460 crore (FY2024). A third-party aggregator reports ₹5,856 crore for FY2025. What remains appears to include:
-
Ayurvedic and wellness products, a large share of which are manufactured by group trust entity Divya Pharmacy (Divya Yog Mandir Trust) and marketed under the Patanjali/Divya brands;
-
dairy;
-
bulk trading;
-
intra-group supply. The exact post-2024 product perimeter is not publicly disclosed.
-
-
Strategic investor/diversifier. Its interests span:
-
general insurance (Magma General Insurance, 73.56% to be acquired; IRDAI approval 28 July 2026);
-
food parks (Nagpur MIHAN; Vizianagaram);
-
wellness and hospital initiatives (with Patanjali Yogpeeth);
-
education/research linkages.
-
-
Financier within the group. Its FY2022 audited statements disclose interest-free loans, advances and corporate guarantees to group companies and other entities.
Revenue model and mix
Product vs. service: Historically almost entirely product revenue (FMCG goods sold through distributors, modern trade, e-commerce and exclusive Patanjali stores).
Licensing/royalty: PAL received ₹5.04 crore of royalty in FY2022 on contract-manufactured products sold by PFL. It also received ₹3.55 crore for transferring the right to sell biscuits, breakfast cereals, edible oil and nutraceuticals to PFL with effect from 2 June 2021 (PAL AR FY2021-22).
Investment/other income: This became material in FY2024. Other income of ₹2,875.29 crore that year included proceeds from the Offer for Sale of PFL shares and income from group entities (PTI/Tofler, FY2024). Subscription and service revenue: none disclosed.
Value-chain position, customers and end-markets
| Dimension | Detail |
|---|---|
| Customer types | Mass-market Indian households (urban and rural); price-sensitive consumers; wellness-oriented consumers; institutional channels (e.g., defence canteen stores historically); export buyers (minor) |
| End-markets | Ayurvedic OTC/wellness, oral care, hair and skin care, home care, dairy (ghee), health foods. After 2022 the food categories sit in PFL. |
| Distribution reach (company claim, 2025) | Products available at ~200,000 retail counters, national chains (Reliance Retail, HyperCity, Star Bazaar) and ~250 Patanjali Mega Stores. Source: Patanjali spokesperson statement quoted in Hindu BusinessLine, March 2025. |
PAL is vertically integrated across:
-
herb sourcing and contract farming (GlobalData profile);
-
manufacturing (Haridwar complex; previously Newasa, Maharashtra; Tezpur, Assam);
-
branding and distribution.
Strategy
Stated strategic themes
PAL publishes no investor-day material. Its stated strategy derives from founder statements and annual-report language:
-
Swadeshi Ayurveda at value prices. Ayurvedic, herbal, traditional and domestic products at reasonable prices, with profit described as not the sole motive (Board's Report FY2022).
-
Vision 2027 (16 Sep 2022). Ramdev announced:
-
IPOs of four group companies within five years: Patanjali Ayurved first, then Patanjali Medicine (described as owning Divya Pharmacy), Patanjali Wellness and Patanjali Lifestyle;
-
a target of ₹5 lakh crore combined market value for five listed entities, including PFL;
-
group turnover rising from ~₹40,000 crore to ₹1 lakh crore in 5–7 years;
-
PFL to target ₹5,000 crore EBITDA and become India's largest oil-palm plantation company;
-
more than 5 lakh jobs.
-
-
Group restructuring around PFL. PAL has consolidated food (2022) and HPC (2024) into the listed vehicle, so that PFL is the FMCG operating platform and PAL retains brand ownership, Ayurveda and new ventures.
-
Diversification into financial services and healthcare. This takes the form of the Magma General Insurance acquisition (2025–26) and hospitals/wellness (Jan 2026).
-
Agro-processing and farmer linkage. Mega food parks are framed as "agriculture revolution" projects for Vidarbha (Nagpur) and North Andhra (Vizianagaram).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Detail |
|---|---|---|---|
| 2024 (completed FY2025) | HPC business sale to PFL (₹1,100 crore) | Portfolio restructuring | Dental, skin, home and hair care moved to PFL |
| 9 Mar 2025 | Nagpur MIHAN Mega Food & Herbal Park | Capacity/agro-processing | ₹1,500 crore; 800 tpd; zero-waste orange processing |
| 12 Mar 2025 | Magma General Insurance SPA | New business (insurance) | ₹4,500 crore valuation; PAL 73.56% |
| Jun 2025 | Vizianagaram mega food park revival | Capacity | 172.84 acres (APIIC) |
| 2,025 | Patanjali Organic Research Institute founded (by Balkrishna) | R&D/agri | Group-level |
| Dec 2025 | MoU with the Russian government | International | Health, wellness and tourism |
| Dec 2025 | Tripura government partnership | Regional investment | ₹300–400 crore project |
| 22 Jan 2026 | Patanjali Emergency & Critical Care Hospital | Healthcare | Described as a hybrid heart, brain and spine care hospital |
| 28 Jul 2026 | IRDAI approval for Magma | Regulatory milestone | Completion window of three months |
Sustainability/ESG commitments
No formal emissions, net-zero or ESG targets are publicly disclosed by PAL. Energy measures disclosed in FY2022:
-
8.3 MWp rooftop solar;
-
boiler fuel substitution with waste herbs (₹77.22 lakh saving);
-
open-access power trading (₹10.23 lakh saving);
-
VFDs and compressed-air optimisation.
Medium-term financial targets/guidance
PAL: no formal guidance. The Vision 2027 aspirations above are founder statements rather than formal company guidance.
PFL (management guidance, FY2027): edible-oil volume growth 3–5%; foods 8–10%; HPC ~15%; HPC margin ~18% or higher; foods margin approaching ~10%; edible oils slightly below 4% (ScanX; The Consumer Daily, May–June 2026). PFL's CEO targeted 10–12% HPC growth and 6–8% foods growth for FY2026 (CNBC-TV18, Dec 2025).
Products & Services
PAL does not publish a SKU-level catalogue with launch years or pricing in its statutory filings. The catalogue below is compiled from company statements, court records and media. Entity attribution after 2022/2024 is uncertain. Many Patanjali-branded food and HPC products are now sold by PFL, and Ayurvedic medicines are largely manufactured by Divya Pharmacy (a trust undertaking).
Ayurvedic & wellness (retained/brand-level; manufacturer often Divya Pharmacy)
| Product / line | Description & positioning | Status / notes |
|---|---|---|
| Patanjali Special Chyawanprash | Classical Ayurvedic immunity tonic. Patanjali claims 51 herbs plus saffron based on Ayurved Sar Sangrah. | Subject of Dabur injunctions (3 Jul 2025; 6/11 Nov 2025). The 2025 appeal was filed by PAL together with PFL, indicating shared involvement. |
| Divya Coronil (tablet/kit) | Marketed in June 2020 as a COVID-19 cure (kit ₹545). Later permitted only as an immunity booster/"supporting measure." | Madras HC barred use of the "Coronil" mark and imposed a ₹10 lakh fine (Aug 2020) |
| Lipidom, Livogrit, Livamrit (Advance) | Ayurvedic formulations marketed for lipid/liver conditions | AYUSH Ministry sought action against ads (Apr 2022). Reported among 14 licences suspended in Apr 2024. |
| BP Grit, Madhugrit, Madhunashini Vati Extra Power | Formulations positioned for blood pressure and diabetes | Reported among the 14 suspended licences (Apr 2024) |
| Swasari range (Gold, Vati, Pravahi, Avaleh), Bronchom, Mukta Vati Extra Power | Respiratory and BP-related formulations | Reported among the 14 suspended licences (Apr 2024) |
| Eyegrit Gold, Patanjali Drishti eye drop | Eye-care formulations | Reported among the 14 suspended licences (Apr 2024) |
| Divya Putrajeevak Beej | Herbal product for infertility | Raised in Parliament (Jul 2015); Uttarakhand health department alleged PCPNDT violation (2016) |
| Honey, Aloe vera, Amla juice | Wellness staples | Amla juice withdrawn by Defence CSD after adverse lab report (Apr 2017) |
Pricing model. Mass-market value pricing positioned below multinational equivalents. Specific price lists are not disclosed.
Home & personal care (transferred to PFL in 2024; brand owned by group)
| Product line | Flagship brands | Notes |
|---|---|---|
| Oral care | Dant Kanti toothpaste | PAL's toothpaste share was reported at 9.62% on a 12-month trailing basis to April 2021 (BloombergQuint) |
| Hair care | Kesh Kanti shampoo/oil | Part of the HPC transfer |
| Skin care | Saundarya range; soaps; cosmetics | Part of the HPC transfer; ASCI notices on hair oil (2016) |
| Home care | Detergents, dishwash, cleaners | Part of the HPC transfer |
Scale reference: HPC revenue was ₹2,475 crore in FY2021 at PAL (BloombergQuint) and ₹627 crore in Q3 FY2026 at PFL (AlphaStreet).
Foods & dairy (transferred to PFL in 2021–2022)
| Product line | Flagship offerings | Notes |
|---|---|---|
| Cow ghee | Patanjali Cow Ghee | Newasa unit transferred to PFL in 2022. Ghee revenue in PFL was ₹467 crore in Q3 FY2026. |
| Biscuits | Doodh biscuit | Doodh crossed ₹1,300 crore annual sales in PFL (FY2026) |
| Staples, cereals, noodles | Atta noodles (launched Nov 2015), breakfast cereals | Biscuit/noodles business moved to Ruchi Soya in 2021 |
| Nutraceuticals | Nutrela-linked range (PFL) | Nutraceuticals turned profitable in H1 FY2025 (PFL) |
| Beverages | Gulab sharbat; fruit juices (Nagpur plant output) | "Sharbat jihad" litigation (Apr–May 2025) |
Adjacent and non-FMCG offerings (group level)
| Offering | Description | Entity / status |
|---|---|---|
| Patanjali Paridhan | Apparel retail (store opened Delhi Nov 2018) | Group company |
| Swadeshi Samriddhi SIM | Co-branded BSNL SIM (May 2018) | Partnership |
| Co-branded prepaid card | Open-loop prepaid card with Ongo (Mar 2024) | GlobalData profile |
| Magma General Insurance | 70+ general insurance products: motor, health, home, personal accident, fire, engineering, marine, liability | PAL to hold 73.56% on completion |
| Wellness & hospitals | Patanjali Wellness centres; Patanjali Emergency & Critical Care Hospital (Jan 2026) | Overseen by Patanjali Yogpeeth per Balkrishna profile |
| Food processing (B2B/B2C) | Nagpur park: orange and other fruit juices, peel oils, pulps, ketchup, jams, pickles (800 tpd) | PAL / PFHP Nagpur subsidiary |
Financial Detail
Group Entities
| Entity | Relationship to PAL | Holding | Notes |
|---|---|---|---|
Patanjali Food & Herbal Park Nagpur Pvt Ltd | Subsidiary | 99.90% | Total assets ₹466.56 cr (FY2022); vehicle for the Nagpur MIHAN park |
Patanjali Food & Herbal Park Noida Pvt Ltd | Subsidiary | 99.92% | Total assets ₹194.36 cr (FY2022) |
Patanjali Food & Herbal Park Jammu Pvt Ltd | Subsidiary | 99.99% | Dormant shell (assets ₹0.12 cr) |
Patanjali Food & Herbal Park Pvt Ltd | Associate | 49.07% | Associated since 30-Mar-2009 |
Patanjali Food & Herbal Park Andhra Sansthan | Associate | 49.00% | Associated since 04-Aug-2017 |
Patanjali Foods Ltd (formerly Ruchi Soya) | Associate | 48.17% (Mar 2022), then 29.61% (Mar 2026) | Listed; reduced via FPO dilution, July 2023 OFS and 2025 secondary sales |
Revenue by Segment and Segment Margins & Growth (%)
| Segment (INR Cr) | FY2020 | FY2021 |
|---|---|---|
Food & dairy products revenue (FY2020 derived) | 6,551 | 6,348 |
Home & personal care revenue (FY2020 derived) | 1,986 | 2,475 |
Ayurvedic products revenue (FY2020 derived, ≤) | 425 | 850 |
Other goods revenue (FY2020 derived) | 67 | 111 |
Segment metric (%) | FY2021 | — |
Food & dairy YoY growth | -3.1 | — |
Home & personal care YoY growth | 24.6 | — |
Ayurvedic products YoY growth (company: "more than doubled") | 100 | — |
Other goods YoY growth | 65.6 | — |
Food & dairy share of revenue (computed) | 64.9 | — |
HPC share of revenue (computed) | 25.3 | — |
Ayurvedic share of revenue (computed) | 8.7 | — |
Operating margin, company level | 10.6 | — |
Segment Margins & Growth (%) and Revenue by Segment
| PFL segment (INR Cr) | FY2025 | FY2026 |
|---|---|---|
Edible oils revenue (FY2025 derived from reported 18.39% growth) | 24,760 | 29,313.54 |
FMCG revenue, incl. food, biscuits, HPC (FY2025 derived from reported 19.95% growth) | 9,327 | 11,188.25 |
Oil palm plantation revenue | — | 1,792.58 |
Total revenue from operations | 33,758.25 | 40,169.58 |
PFL segment metric (%) | FY2026 | — |
FMCG share of revenue | 27.60 | — |
FMCG share of EBITDA (ex-unallocable) | 61.13 | — |
FMCG EBITDA margin | 10.81 | — |
Q4 FY2026 edible oil EBITDA margin | 2.58 | — |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 9,810.74 | 10,664.46 | 7,533.88 | 6,460.03 | 5,855.69 |
Other income (INR Cr) | 61.13 | 66.49 | 46.18 | 2,875.29 | — |
Total income (INR Cr) | 9,871.87 | 10,730.95 | 7,580.06 | 9,335.32 | — |
Total expenditure before depreciation (INR Cr) | 9,060.06 | 9,992.36 | — | — | — |
Profit before depreciation & tax, EBITDA proxy (INR Cr) | 811.81 | 738.59 | — | — | — |
Depreciation (INR Cr) | 172.63 | 145.41 | — | — | — |
Profit before tax (INR Cr) | 639.18 | 593.18 | — | — | — |
Tax expense (INR Cr) | 154.62 | 161.38 | — | — | — |
Net profit after tax (INR Cr) | 484.56 | 431.80 | 578.44 | 2,901.10 | — |
EPS basic, computed on 4,13,22,108 shares (INR) | 117.26 | 104.50 | 139.98 | 702.07 | — |
Dividend per share (INR) | — | 0 | — | — | — |
Advertising & promotion, PTI series (INR Cr; FY2023 derived) | — | — | 386.46 | 422.33 | — |
Advertising & promotion, afaqs series (INR Cr) | — | — | 173.13 | 424.70 | — |
CSR spend (INR Cr) | — | 11.38 | — | — | — |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 8.21 | 8.70 | -29.35 | -14.25 | -9.36 |
PBDT (EBITDA-proxy) margin (%) | 8.27 | 6.93 | — | — | — |
PBT margin (%) | 6.51 | 5.56 | — | — | — |
Net margin on revenue from operations (%) | 4.94 | 4.05 | 7.68 | 44.91 | — |
Other income as % of total income (%) | 0.62 | 0.62 | 0.61 | 30.80 | — |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Paid-up equity share capital (INR Cr) | 41.32 | 41.32 | — | — | — |
Equity shares outstanding (crore shares) | 4.1322108 | 4.1322108 | — | — | — |
| — | 250 | 425 | 425 | 175 | 0 |
Loans to directors and relatives outstanding during year, later recovered (INR Cr) | — | 22.83 | — | — | — |
GST demand deposited under protest (INR Cr) | — | 75.09 | — | — | — |
Key Financials
| Metric | FY2021 | FY2022 |
|---|---|---|
Dividends paid (INR Cr) | — | 0 |
Share buybacks (INR Cr) | 0 | 0 |
Foreign exchange outgo on capital goods and services (INR Cr) | — | 52.14 |
Margin Analysis (%) (FY2022)
| Ratio | FY2022 |
|---|---|
R&D as % of revenue (%) | 0.0004 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
PFL revenue from operations (INR Cr) | — | — | 31,721 | 33,758.25 | 40,169.58 |
PFL total income (INR Cr) | — | 31,821.45 | 31,961.62 | 34,289.40 | 40,347.78 |
PFL net profit (INR Cr) | 740.38 | 886.44 | 765.15 | 1,301.34 | 1,814.47 |
PFL EBITDA excluding exceptional items (INR Cr) | — | — | — | — | 1,931.52 |
Region (INR Cr) Overview
| Region (INR Cr) | FY2022 |
|---|---|
Export earnings, accrual basis | 67.32 |
Domestic revenue (derived: revenue from operations less exports) | 10,597.14 |
Export share of revenue (%, computed) | 0.63 |
Country Overview
| Country | Activity | Status | Source |
|---|---|---|---|
India | Core market; all manufacturing and distribution | Active | PAL AR |
Nepal | Herbal factory/herbal park plans (2015); Nepal's drug regulator rejected six Patanjali products (2017); Nepal halted distribution of donated Coronil kits (2021) | Mixed | Webdunia; Firstpost; The Hindu |
Bhutan | Halted distribution of donated Coronil (2021) | — | Wikipedia |
United Kingdom | UK regulator warned of action against unauthorised Coronil sales (2020) | Regulatory caution | BBC |
United States | USFDA flagged different dietary/medicinal claims on Patanjali products | Regulatory caution | — |
Russia | MoU with the Russian government to promote health, wellness and tourism (Dec 2025) | Early-stage | Economic Times (6 Dec 2025) |
Middle East | Listed as an area served | Not quantified | Wikipedia |
Pfl Market Metric Details
| PFL market metric | Value | Date | Source |
|---|---|---|---|
Share price | ₹343.40 | 27 Jul 2026 | Kotak Neo |
52-week / six-year low | ₹328.05–₹328.20 | 15 Jul 2026 | Business Today; Angel One |
1-year price change (%) | -46.64 | to 27 Jul 2026 | Kotak Neo |
6-month price change (%) | -32.8 | to 27 Jul 2026 | Kotak Neo |
YTD 2026 change (%) | approx. -37.5 | to 15 Jul 2026 | DSIJ / Bajaj Broking |
Market capitalisation | ~₹37,132 crore | 15 Jul 2026 | Business Today |
Market capitalisation at peak period | ~₹65,000 crore (Sep 2025); reported peak ~₹73,000 crore | Sep 2025 | Business Today; The Consumer Daily |
P/E (trailing) | ~24.4x (from ~30x in May 2026) | Jul 2026 | askfuzz (secondary) |
PAL's direct stake | 29.61% | Mar 2026 | marketsmojo |
PAL look-through value of PFL stake (computed) | ~₹10,995 crore | 15 Jul 2026 | 29.61% × ₹37,132 crore |
Promoter group holding | 68.25% | Jun 2026 | Outlook Business |
PFL long-term credit rating | ICRA AA- (Stable), upgraded | 30 Jun 2026 | PFL filing via FilingReader |
Analyst stance | Mixed. Some BUY calls at ₹700 target (early 2026); ICICI Securities cut its FY2027 EPS estimate by ~14% (mid-2026). | 2026 | askfuzz; The Consumer Daily |
PFL dividend per share (INR)
| PFL dividend per share (INR) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total dividend per share (FY2024 and FY2025 pre-bonus; FY2026 post-2:1 bonus) | 14 | 10 | 5 |
Credit Ratings
| Agency | Rating / action | Date | Status |
|---|---|---|---|
ICRA | Upgraded A- → A+ (Stable), ₹300 crore fund-based; A2+ → A1 short-term | Jan 2017 | Historical |
Brickwork | AA- (Stable) | 2016 | Historical |
CARE | Downgraded A+ → A- (credit watch, developing implications); then withdrawn at company request | Oct 2019 | Withdrawn |
ICRA | Downgraded to BBB, citing lack of adequate information | Oct 2019 | Historical |
Brickwork | Outlook revised to negative; PFHP Nagpur (PAL-guaranteed) cut to BBB+ (CE) | Oct–Nov 2019 | Historical |
Moody's / S&P / Fitch | Not rated | — | — |
Capital Instruments
| Instrument | Amount (INR Cr) | Coupon (%) | Issue | Maturity | Status |
|---|---|---|---|---|---|
Secured listed NCD | 250 | 10.10 | 29 May 2020 | 28 May 2023 | Scheduled redemption passed |
Secured listed NCD | 175 | 9.25 | 19 May 2021 | 18 May 2024 | Scheduled redemption passed |
Bank facilities (PNB-led consortium) | — | — | — | — | Secured partly by promoter share pledge (FY2022) |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
PAL issues no formal guidance. Founder-level aspirations (Vision 2027) remain the only stated targets:
-
four IPOs by ~2027;
-
₹1 lakh crore group turnover within 5–7 years of 2022;
-
₹5 lakh crore combined market value.
By the evidence, these targets are materially behind schedule. PFL's market capitalisation was ~₹37,000 crore in July 2026, and no PAL DRHP has been located. Consensus estimates for PAL do not exist. For PFL, management guides FY2027 volume growth of 3–5% in edible oils, 8–10% in foods and ~15% in HPC.
Bull case
| # | Argument | Evidence |
|---|---|---|
| 1 | Sum-of-parts upside. A recovery in PFL plus completion of Magma could re-rate PAL's net asset value. | PFL earnings have held up: Q1 FY2027 PAT +86% YoY; ICRA upgraded to AA- (Jun 2026). Magma premiums grew 22% CAGR over FY2021–FY2025. |
| 2 | Distribution flywheel into insurance. Cross-selling simple motor/health covers through ~200,000 counters could scale Magma from its ~1% share. | Company distribution claims (Mar 2025); Magma's 70+ products |
| 3 | Asset-light parent with crystallised cash. Sales have realised roughly ₹3,600 crore or more since 2022 (₹690 crore + ₹1,100 crore + ₹1,815 crore + OFS proceeds), while debt matured. | PAL AR; PTI; Outlook Business |
Bear case
| # | Argument | Evidence |
|---|---|---|
| 1 | Shrinking, low-margin core. Revenue from operations is down ~45% from its FY2022 peak. Historical PBT margins were 5–6%, and FY2024 profits were inflated by one-offs. | Section 6 |
| 2 | Escalating legal and regulatory drag. Four court restraints on advertising in two years, a reported MCA probe and multiple state DMR Act cases constrain the founder-led marketing model. | Section 19 |
| 3 | Concentration and governance. About 98.5% of PAL is owned by one individual, roughly half of it pledged. Disclosure is opaque, with auditor-flagged director loans. The single largest asset (PFL) fell ~47% in a year. Insurance requires fit-and-proper governance and ongoing capital. | PAL AR FY2022; Kotak Neo |
Catalysts and monitorables (next 12 months)
-
Completion of the Magma acquisition within the IRDAI window (~28 Oct 2026); funding mix; capital infusion; board reconstitution.
-
PAL FY2026 RoC financials (expected late 2026). Watch for confirmation of FY2025/FY2026 revenue classification, other income, net debt and Magma funding.
-
PFL quarterly results. Edible-oil margin trajectory (Q4 FY2026 EBITDA margin was 4.0%); HPC growth; dividend policy.
-
Litigation outcomes. Dabur appeals and suits; Hamdard contempt; any MCA action; Kerala cases.
-
IPO signals under Vision 2027 (DRHP filing or banker mandates).
-
Further PFL stake sales or block deals by the promoter group (block deals of 1.48% in Feb 2026 and 1.5% in Jul 2026).
Analyst verdict
Patanjali Ayurved Limited is no longer the company that unsettled Indian FMCG in 2016. It has moved from operating champion to holding company. Between 2019 and 2024, management executed a coherent if self-serving restructuring:
-
it bought Ruchi Soya out of insolvency for ₹4,350 crore;
-
it used that listed shell to absorb Patanjali's food (₹690 crore) and home-and-personal-care (₹1,100 crore) franchises;
-
it sold down PFL shares to meet public-float rules, booking ₹2,875 crore of other income in FY2024 alone.
The result is a parent whose operating revenue has roughly halved from its FY2022 peak. Its economic value now rests on three pillars:
-
a 29.6% stake in a commodity-heavy listed affiliate;
-
a pending controlling stake in a sub-scale general insurer;
-
a residual Ayurvedic and dairy business whose margins have historically been a third or less of peers'.
The bull thesis depends on PFL re-rating and on Patanjali's rural distribution transforming Magma. Both are plausible, but neither is yet evidenced. PFL's FY2026 headline profit relied on a ₹788 crore tax refund, and its edible-oil margins have compressed. Patanjali has no insurance operating history, and Magma will need solvency capital.
The bear thesis is better documented:
-
the founder-centric marketing model has been repeatedly curtailed by the Supreme Court and the Delhi High Court;
-
governance markers (pledged promoter equity, auditor-flagged director loans, related-party CSR, a reported MCA inquiry) remain weak;
-
disclosure is too thin for institutional underwriting.
The Vision 2027 promises of four IPOs and ₹5 lakh crore in combined market value look unattainable on current trajectory.
Verdict: PAL is best viewed as a closely held, governance-discounted holding company with real but volatile asset value. That value is roughly ₹11,000 crore in PFL alone at July 2026 prices. Execution on Magma, legal normalisation and a transparent IPO-grade disclosure regime are the three conditions for any sustained re-rating. Until then, counterparties should price in elevated legal, governance and key-person risk.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Background | Age / DOB | Remuneration |
|---|---|---|---|---|---|
Acharya Balkrishna | Managing Director (also described as Chairperson & CEO); promoter, ~98.5% shareholder | Co-founder, 2006 | Sanskrit scholar and Ayurveda researcher. General Secretary of Patanjali Yogpeeth, Divya Yog Mandir Trust, Patanjali Research Foundation and Patanjali Gramodhyog Trust. Non-executive Chairperson of PFL (director since 18-Dec-2019). Forbes estimated his net worth at US$2.3bn (May 2021). | Born 1972 (25 Jul per NSE filing; 4 Aug per Wikipedia, a discrepancy) | Nil — PAL pays no remuneration or sitting fees to any director (AR FY2021-22) |
Swami Ramdev | Co-founder, public face and strategic decision-maker; holds no equity and no board seat at PAL | — | Yoga guru; director of PFL (re-appointed at PFL's Sep 2025 AGM) | — | Not applicable |
Ram Bharat | Non-Executive, Non-Independent Director | On board as of FY2022 and listed in 2026 profiles | Reported to be Swami Ramdev's brother; group executive | — | Nil |
Rakesh Mittal | Non-Executive, Non-Independent Director; Chair of CSR and NRC committees (FY2022) | Re-appointed by rotation, Sep 2022 | — | — | Nil |
Ajai Kumar Arya | Independent Director | On board FY2022; listed in 2026 profiles | — | — | Nil |
Dr. Sumedha | Independent Director | — | — | — | Nil |
Sadhvi Devvarenya | Independent Director (term 22-Jul-2022 to 21-Jul-2027) | Appointed 22 Jul 2022 | B.E. (Electronics & Communication), Osmania University; M.A. from University of Patanjali | 31 (in 2022) | Nil |
Swami Arshdev | Non-Executive Director | — | — | — | Nil |
Rajneesh Mishra | Non-Executive Director | Listed in GlobalData profile (2025–26) | — | — | — |
Y. D. Arya | Chief Financial Officer | KMP as of FY2022 | — | — | ₹39.05 lakh (FY2022), up 7.5% |
Vineet Pant | Company Secretary | KMP as of FY2022 | FCS | — | ₹7.42 lakh (FY2022) |
Kamal Nayan Singh | Former CEO; briefly Additional Director (15 Apr–25 May 2022) | CEO from 12 Feb 2018 | A.T.I. (Manchester); 33 years' experience; previously Creative Group, Mumbai | 56 (FY2022) | ₹1.15 crore (FY2022) |
Anita Nayyar | Chief Operating Officer | — | Former media-agency executive | — | — |
Saikat Dutta | COO, Patanjali Media | Since 2023 (GlobalData) | — | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
15 Apr 2022 | Kamal Nayan Singh appointed Additional Director | Resigned 25 May 2022 for personal reasons |
13 May 2022 | Swami Muktanand (Executive Director, Audit Chair, promoter shareholder) died | His 1,000 shares were transferred to Yogakshem Sansthan (27 Jul 2022) |
22 Jul 2022 | Sadhvi Devvarenya (Independent) and Swami Arshdev (Non-Executive) appointed | Regularised at the Sep 2022 AGM |
2023 onward | Saikat Dutta named COO, Patanjali Media | GlobalData |
Major Shareholders
| Holder | Shares | Stake | Date | Source |
|---|---|---|---|---|
Acharya Balkrishna | 4,07,19,912 | 98.54% | 31 Mar 2022 | PAL AR FY2021-22 |
Swami Muktanand (deceased) → Yogakshem Sansthan | 1,000 | 0.002% | 27 Jul 2022 | PAL AR FY2021-22 |
Others (individuals/group entities) | Balance | ~1.46% | 31 Mar 2022 | Derived |
Institutional investors | — | 0% | — | Unlisted; no institutional capital disclosed |
Competitive Landscape
Competitors by Segment
| Segment | Competitors | Notes |
|---|---|---|
Ayurvedic OTC / health supplements (chyawanprash, honey, tonics) | Dabur India; Emami (Zandu); Baidyanath; Himalaya Wellness; Hamdard (Unani/beverages); Kapiva | Dabur holds ~60–61% of the >₹1,000 crore chyawanprash market (Storyboard18; Exchange4media, 2025) |
Oral care | Colgate-Palmolive (India); Hindustan Unilever; Dabur (Red, Meswak) | Dant Kanti reached ~9.6% toothpaste share (12M to Apr 2021) |
Hair & skin care | HUL; Emami; Marico; Dabur; Himalaya; Godrej Consumer | HUL launched "Lever Ayush" (c.2016) in response to Patanjali |
Home care | HUL; Jyothy Labs; Godrej Consumer; Reckitt | — |
Dairy / ghee | Amul (GCMMF); Mother Dairy; state cooperatives | Ghee sits mostly in PFL post-2022 |
Foods (via PFL) | Britannia, ITC, Nestlé India, Adani Wilmar/AWL Agri Business | Edible oils, biscuits, staples |
General insurance (Magma) | ICICI Lombard, Bajaj Allianz/General, New India Assurance, HDFC ERGO, Tata AIG and others | Magma share ~1.05% |
Peer Comparison FY2026
| Company | Fiscal year | Revenue from operations (INR Cr) | YoY growth (%) | Operating/EBITDA margin (%) | Net margin (%) | R&D intensity (%) | Source |
|---|---|---|---|---|---|---|---|
Patanjali Ayurved (standalone) | FY2024 (latest verified) | 6,460.03 | -14.25 | — | 44.91 (other-income distorted); FY2022 core 4.05 | 0.0004 (FY2022) | PTI/Tofler; PAL AR |
Dabur India (consolidated) | FY2026 | 13,193 | 5.0 | 18.6 (operating) | 14.4 | — | Dabur AGM presentation via Investywise; Stockanalysis |
Emami (consolidated) | FY2026 | 3,779.5 | -0.8 | 25.5 (EBITDA) | 20.5 | — | Emami filings via FPJ/FilingReader |
Colgate-Palmolive (India) | FY2026 | 5984 (net sales) | — | — | — | — | Reuters via Zerodha |
Patanjali Foods (affiliate) | FY2026 | 40,169.58 | 19.0 | 4.8 (EBITDA ex-exceptional, computed) | 4.5 | — | PFL filings |
“—” = not publicly disclosed.
Recent Developments
--



